RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Arrowhead Pharmaceuticals Stock

Arrowhead Pharmaceuticals P/E 2025

Arrowhead Pharmaceuticals P/E

-4.35

Ticker

ARWR

ISIN

US04280A1007

WKN

A2AGYB

As of Mar 4, 2025, Arrowhead Pharmaceuticals's P/E ratio was -4.35, a 15.69% change from the -3.76 P/E ratio recorded in the previous year.

The Arrowhead Pharmaceuticals P/E history

Arrowhead Pharmaceuticals Aktienanalyse

What does Arrowhead Pharmaceuticals do?

Arrowhead Pharmaceuticals Inc is a biotechnology company that develops and commercializes RNA-based therapeutics. The company is headquartered in Pasadena, California and was founded in 2007. Arrowhead's history began when a group of scientists at the University of Texas came together to work on the development of RNA-based therapeutics. In 2007, Arrowhead was established and the company's patented TRiM™ (Targeted RNAi Molecules) technology was developed to specifically overcome barriers in RNAi-based therapeutics. The company is divided into several divisions, including Hepatitis B, cardiovascular, metabolic disorders, and oncology. Arrowhead has developed a range of RNAi-based investigational products, including ARC-520, which is being developed for the treatment of Hepatitis B and is currently in clinical trials. ARC-520 is designed to inhibit the formation and release of viral particles in liver cells, thereby halting the progression of the disease. Arrowhead has also developed products for the treatment of life-threatening diseases such as Alpha-1 Antitrypsin Deficiency (AAT) and hypertriglyceridemic pancreatitis (HTG). The treatments offered by Arrowhead aim to utilize RNA in disease treatment where other methods have failed. Arrowhead Pharmaceuticals Inc's business model is based on the discovery, development, and commercialization of RNAi-based therapeutics. The company collaborates with partners to accelerate the development and commercialization of its products. Arrowhead has a strategic partnership with Johnson & Johnson Pharmaceuticals Research & Development, LLC. Arrowhead Pharmaceuticals Inc is listed on the NASDAQ stock exchange under the ticker symbol ARWR. The company employs approximately 150 employees, including scientists, researchers, and specialists specialized in RNA biology. Recently, Arrowhead Pharmaceuticals Inc partnered with Takeda Pharmaceutical Co. Ltd. to develop RNAi-based therapeutics. This partnership aims to accelerate the development of RNAi-based therapeutics and optimize the company's potential in the field of RNA biology. In summary, Arrowhead Pharmaceuticals is a biotechnology company specializing in RNA biology. The company has developed a patented TRiM™ technology that specifically overcomes barriers in disease therapy with RNAi-based therapeutics. Arrowhead has developed several products for the treatment of life-threatening diseases and collaborates with partners to accelerate the development of its products and optimize commercialization. Arrowhead Pharmaceuticals Inc is an innovative player in the biotechnology field and strives to improve and revolutionize the common practice of RNAi-based therapeutics. Arrowhead Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Arrowhead Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Arrowhead Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Arrowhead Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Arrowhead Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Arrowhead Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Arrowhead Pharmaceuticals stock

What is the price-to-earnings ratio of Arrowhead Pharmaceuticals?

The price-earnings ratio of Arrowhead Pharmaceuticals is currently -4.35.

How has the price-earnings ratio of Arrowhead Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Arrowhead Pharmaceuticals has increased by 15.69% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Arrowhead Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Arrowhead Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Arrowhead Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Arrowhead Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Arrowhead Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Arrowhead Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Arrowhead Pharmaceuticals?

Some factors that influence the price-earnings ratio of Arrowhead Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Arrowhead Pharmaceuticals pay?

Over the past 12 months, Arrowhead Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arrowhead Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Arrowhead Pharmaceuticals?

The current dividend yield of Arrowhead Pharmaceuticals is .

When does Arrowhead Pharmaceuticals pay dividends?

Arrowhead Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Arrowhead Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arrowhead Pharmaceuticals located?

Arrowhead Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arrowhead Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arrowhead Pharmaceuticals from 3/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/4/2025.

When did Arrowhead Pharmaceuticals pay the last dividend?

The last dividend was paid out on 3/4/2025.

What was the dividend of Arrowhead Pharmaceuticals in the year 2024?

In the year 2024, Arrowhead Pharmaceuticals distributed 0 USD as dividends.

In which currency does Arrowhead Pharmaceuticals pay out the dividend?

The dividends of Arrowhead Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Arrowhead Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Arrowhead Pharmaceuticals

Our stock analysis for Arrowhead Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arrowhead Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.